Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

AMPK-activation by Metformin in FSGS: AMP-FSGS — Stella

Home/Focal Segmental Glomerulosclerosis/AMPK-activation by Metformin in FSGS: AMP-FSGS

View on ClinicalTrials.gov

Recruiting

Back to Focal Segmental Glomerulosclerosis trials

AMPK-activation by Metformin in FSGS: AMP-FSGS

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

Yale New Haven Hospital, New Haven, Connecticut

Mount Sinai Hospital, New York, New York

Key details

Phase

Early testing / Safety & dosing

Sponsor

Yale University

Collaborators

United States Department of Defense

Enrollment target

~30 participants

Started

December 2023

Primary completion

November 2027

Age range

18 Years – 80 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.